ARK Investment Management LLC Sells 310,088 Shares of Personalis, Inc. (NASDAQ:PSNL)

ARK Investment Management LLC trimmed its holdings in shares of Personalis, Inc. (NASDAQ:PSNL) by 4.4% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 6,775,435 shares of the company’s stock after selling 310,088 shares during the quarter. ARK Investment Management LLC owned 0.10% of Personalis worth $39,162,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Olympiad Research LP bought a new stake in shares of Personalis during the fourth quarter worth approximately $59,000. abrdn plc bought a new stake in shares of Personalis during the fourth quarter worth approximately $1,722,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Personalis during the fourth quarter worth approximately $87,000. SG Americas Securities LLC bought a new stake in shares of Personalis during the fourth quarter worth approximately $63,000. Finally, Barclays PLC raised its stake in shares of Personalis by 45.4% during the third quarter. Barclays PLC now owns 65,468 shares of the company’s stock worth $352,000 after buying an additional 20,444 shares during the last quarter. 61.91% of the stock is owned by institutional investors.

Personalis Stock Performance

Shares of NASDAQ:PSNL opened at $4.23 on Wednesday. Personalis, Inc. has a 52 week low of $1.13 and a 52 week high of $7.20. The company has a market capitalization of $298.84 million, a PE ratio of -2.52 and a beta of 1.73. The company has a 50 day moving average price of $5.43 and a two-hundred day moving average price of $5.05.

Wall Street Analyst Weigh In

PSNL has been the subject of a number of recent research reports. HC Wainwright dropped their price target on shares of Personalis from $11.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, January 27th. Needham & Company LLC reaffirmed a “buy” rating and issued a $7.25 target price on shares of Personalis in a research note on Wednesday, January 8th. Finally, Lake Street Capital upped their target price on shares of Personalis from $7.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.